Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tyrosine Kinase Inhibitors in Non-advanced Systemic Mastocytosis.

Immunology and allergy clinics of North America - 1 Nov 2023

Akin Cem

Abstract excerpt

Systemic mastocytosis is associated with KIT D816V mutation in more than 90% of cases. Patients with non-advanced forms of mastocytosis (indolent systemic mastocytosis, bone marrow mastocytosis, and smoldering systenic mastocytosis) have a low rate of progession to advanced variants and generally have a comparable life expectancy to age-matched general population. Symptomatology in non-advanced mastocytosis is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Mast Cells
Share to Mastocytosis, Systemic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Share to Treatment Outcome

Share to Tyrosine Kinase Inhibitors

Source

Identifiers

PMID: 37758410
DOI: 10.1016/j.iac.2023.05.001

Genes

KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tyrosine Kinase Inhibitors in Non-advanced Systemic Mastocytosis.PMID 37758410Read ↗

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.Semantic proximity Read ↗

Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy.Semantic proximity Read ↗

Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.Semantic proximity Read ↗

Systemic Mastocytosis: State of the Art.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.Semantic proximity Read ↗

Avapritinib for Systemic Mastocytosis.Semantic proximity Read ↗

Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.Semantic proximity Read ↗

Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.Semantic proximity Read ↗

Recent advances in the understanding and therapeutic management of mastocytosisSemantic proximity Read ↗

Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.Semantic proximity Read ↗

How I treat patients with advanced systemic mastocytosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.